ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent

ACRS 2.425

+3.6%

2:46 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: BioHero	10/11/2019 3:48:41 PM
	of 23

William Blair sees 'significant value disconnect' in Aclaris Therapeutics William Blair analyst Tim Lugo maintains an Outperform rating on Aclaris Therapeutics after the company announced the divestiture of worldwide rights for Rhofade to EPI Health for up to $55M. The analyst says the deal value compares well with his previously estimated net present value for the Rhofade program of $65M. The divestiture is a first step in management extracting value from its commercial portfolio as the company has signaled additional partnerships and divestitures, Lugo tells investors in a research note. He continues to see a "significant value disconnect" with Aclaris shares trading at less than half of cash. The analyst sees "some promising early-stage assets, and near-term potential for strategic partnerships." Read more at: thefly.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext